Neutralization of lipopolysaccharide effects in liver diseases, the quest for the holy grail
Arnaud Galbois, Dominique Thabut, Richard Moreau, Didier Lebrec – 12 January 2011
Constitutional telomerase mutations are genetic risk factors for cirrhosis
Rodrigo T. Calado, Jennifer Brudno, Paulomi Mehta, Joseph J. Kovacs, Colin Wu, Marco A. Zago, Stephen J. Chanock, Thomas D. Boyer, Neal S. Young – 12 January 2011 – Some patients with liver disease progress to cirrhosis, but the risk factors for cirrhosis development are unknown. Dyskeratosis congenita, an inherited bone marrow failure syndrome associated with mucocutaneous anomalies, pulmonary fibrosis, and cirrhosis, is caused by germline mutations of genes in the telomerase complex. We examined whether telomerase mutations also occurred in sporadic cirrhosis.
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection
Amir Moghaddam, Espen Melum, Nils Reinton, Helmer Ring‐Larsen, Hans Verbaan, Kristian Bjøro, Olav Dalgard – 12 January 2011 – Polymorphisms near the IL28B gene, which code for interferon (IFN)‐λ3, predict response to pegylated interferon‐α (PEG‐IFN) and ribavirin treatment in hepatitis C virus (HCV) genotype 1 infected patients. Follow‐up studies of the effect of IL28B gene in HCV non–genotype 1 infected patients have almost always used predominantly HCV genotype 2–infected or mixed genotype 2/3–infected cohorts with results partly conflicting with HCV genotype 1.
Drug‐induced autoimmune hepatitis: An easily reversible type of liver fibrosis?
Ersan Ozaslan – 12 January 2011
Interferon‐β and interferon‐λ signaling is not affected by interferon‐induced refractoriness to interferon‐α in vivo
Zuzanna Makowska, Francois H. T. Duong, Gaia Trincucci, David F. Tough, Markus H. Heim – 12 January 2011 – Therapy of chronic hepatitis C with pegylated interferon α (pegIFN‐α) and ribavirin achieves sustained virological responses in approximately half of the patients. Nonresponse to treatment is associated with constitutively increased expression of IFN‐stimulated genes in the liver already before therapy.
Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification
Maxime Ronot, Stephane Bahrami, Julien Calderaro, Dominique‐Charles Valla, Pierre Bedossa, Jacques Belghti, Valérie Vilgrain, Valérie Paradis – 12 January 2011 – Hepatocellular adenomas (HCAs) are divided into genotype/phenotype subgroups associated with different evolutive profiles. Therefore, recognition of subtype is of clinical importance in patient management. Magnetic resonance imaging (MRI) is considered the most informative imaging modality and liver biopsy a key diagnostic tool whose role in HCA subtyping has never been extensively studied.
The deleterious effects of propranolol on patients with cirrhosis
Cumali Efe, Tugrul Purnak, Ersan Ozaslan – 12 January 2011
Does cardiac dysfunction explain deleterious effects of beta‐blockers in cirrhosis and refractory ascites?
Aleksander Krag, Flemming Bendtsen, Søren Møller – 12 January 2011
Reply
Jasmohan S. Bajaj, Oliviero Riggio – 12 January 2011
Transcription coactivator mediator subunit MED1 Is required for the development of fatty liver in the mouse
Liang Bai, Yuzhi Jia, Navin Viswakarma, Jiansheng Huang, Aurore Vluggens, Nathan E. Wolins, Nadereh Jafari, M. Sambasiva Rao, Jayme Borensztajn, Gongshe Yang, Janardan K. Reddy – 12 January 2011 – Peroxisome proliferator‐activated receptor‐γ (PPARγ), a nuclear receptor, when overexpressed in liver stimulates the induction of adipocyte‐specific and lipogenesis‐related genes and causes hepatic steatosis.